Sanofi American Depositary Receipt (SNY)
CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports
Private equity firm Clayton Dubilier & Rice (CD&R) is nearing a deal to acquire Sanofi's consumer health unit for about 15 billion euros ($16.4 billion), Bloomberg News reported on Thursday.
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
Drug developer Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary goals.
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA).
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as “smoker's lung.”
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday.
Are Investors Undervaluing Sanofi (SNY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners, Bloomberg News reported on Tuesday.
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
